OS Therapies Incorporated, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $6.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors surrounding OS Therapies Incorporated’s recent developments. The company has announced promising interim results from its Phase 2b trial of OST-HER2, a novel cancer immunotherapy targeting HER2-expressing cancer cells in recurrent osteosarcoma. The data revealed that 66.6% of patients treated with OST-HER2 achieved a 2-year overall survival rate, significantly higher than the 40% observed in historical controls, indicating a strong therapeutic potential.
Additionally, OS Therapies is making strides towards regulatory approval, with an End-of-Phase 2 meeting with the FDA scheduled and a BLA number already assigned, suggesting a favorable pathway for accelerated approval. The OST-HER2 therapy holds several FDA designations, including Orphan, Fast Track, and Rare Pediatric Disease, which could lead to a priority review voucher, offering a substantial non-dilutive capital opportunity. These factors, combined with the significant unmet medical need in osteosarcoma treatment, underpin McCarthy’s optimistic outlook and Buy rating for the stock.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OSTX in relation to earlier this year.